Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G6 | O60733 | 2/20 | 0.44 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | FASN | P49327 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29097002 | 0.83 | PLA2G6 (0.43) | PLA2G6PLA2G4AFASNGAAL3MBTL1 | |
| SCHEMBL21804589 | 0.81 | NAAA (0.44) | GLANPSR1L3MBTL1 | |
| SCHEMBL7417047 | 0.80 | GLA (0.66) | GLANPSR1FASN | |
| SCHEMBL22409642 | 0.77 | ALDH1A1 (0.44) | GAAL3MBTL1 | |
| SCHEMBL19376943 | 0.77 | TAAR1 (0.46) | PLA2G6PLA2G4AFASNTAAR1 | |
| SCHEMBL22481259 | 0.77 | ALDH1A1 (0.43) | GLANPSR1GAAL3MBTL1 | |
| SCHEMBL6174462 | 0.76 | PLA2G6 (0.41) | PLA2G6PLA2G4ATAAR1 | |
| SCHEMBL3097535 | 0.74 | GLA (0.48) | GLANPSR1GAAL3MBTL1TAAR1 | |
| SCHEMBL23459023 | 0.74 | LMNA (0.39) | — | |
| SCHEMBL23459024 | 0.74 | LMNA (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172392-A1 | AMINE-BASED AND AMIDE-BASED INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) ENZYME ACTIVITY AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT OF DISEASES | SALTER-CID LUISA M (US) | 2012-07-05 | — | — | US | disclosed |
| US-20070078157-A1 | Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO)enzyme activity and VAP-1 mediated adhesion useful for treatment of diseases | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078157-A1 | Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO)enzyme activity and VAP-1 mediated adhesion useful for treatment of diseases | VCAM1, AOC2, AOC1 | PLA2G6 3988/4885PLA2G4A 3959/4885GLA 3070/4885 |
| US-20120172392-A1 | AMINE-BASED AND AMIDE-BASED INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) ENZYME ACTIVITY AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT OF DISEASES | VCAM1, AOC2, AOC1 | PLA2G6 3988/4885PLA2G4A 3959/4885GLA 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.